ArticleStem cells (Dayton, Ohio)2014
Systemic anticancer neural stem cells in combination with a cardiac glycoside for glioblastoma therapy.
Article in Stem cells (Dayton, Ohio), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 22 citations in OpenAlex.
- Auto-loaded TRAIL-exosomes derived from induced neural stem cells for brain cancer therapy.Journal of controlled release : official journal of the Controlled Release Society · 2024Article
- Role and mechanism of neural stem cells of the subventricular zone in glioblastoma.World journal of stem cells · 2021Review
- Feasibility of intracerebrally administering multiple doses of genetically modified neural stem cells to locally produce chemotherapy in glioma patients.Cancer gene therapy · 2021Article
- Olfactory Ensheathing Cells: A Trojan Horse for Glioma Gene Therapy.Journal of the National Cancer Institute · 2019Article
- Ex vivo perfusion-based engraftment of genetically engineered cell sensors into transplantable organs.PloS one · 2019Article
- Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide targeting de novo DNA synthesis, irrespective of molecular subtype.Neuro-oncology · 2018Article
- Elimination of undifferentiated human embryonic stem cells by cardiac glycosides.Scientific reports · 2017Article
- Neural Stem Cell-Based Anticancer Gene Therapy: A First-in-Human Study in Recurrent High-Grade Glioma Patients.Clinical cancer research : an official journal of the American Association for Cancer Research · 2017Article
- Imaging Tumor Vascularity and Response to Anti-Angiogenic Therapy Using Gaussia Luciferase.Scientific reports · 2016Article
- Article
- Therapeutic potential of targeting microRNA-10b in established intracranial glioblastoma: first steps toward the clinic.EMBO molecular medicine · 2016Article
- Neural Stem Cell Carriers for the Treatment of Glioblastoma Multiforme.EBioMedicine · 2015Review
- Mesenchymal stem cells secretome as a modulator of the neurogenic niche: basic insights and therapeutic opportunities.Frontiers in cellular neuroscience · 2015Review
Corrections and comments
- Erratum issuedCorrigendum.2016
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
The tumor-tropic properties of neural stem cells (NSCs) have been shown to serve as a novel strategy to deliver therapeutic genes to tumors. Recently, we have reported that the cardiac glycoside lanatoside C (Lan C) sensitizes glioma cells to the anticancer agent tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Here, we engineered an FDA-approved human NSC line to synthesize and secrete TRAIL and the Gaussia luciferase (Gluc) blood reporter. We showed that upon systemic injection, these cells selectively migrate toward tumors in the mice brain across the blood-brain barrier, target invasive glioma stem-like cells, and induce tumor regression when combined with Lan C. Gluc blood assay revealed that 30% of NSCs survived 1 day postsystemic injection and around 0.5% of these cells remained viable after 5 weeks in glioma-bearing mice. This study demonstrates the potential of systemic injection of NSCs to deliver anticancer agents, such as TRAIL, which yields glioma regression when combined with Lan C.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.